These findings illuminate the potential significant roles of the low-biomass tumor microbiome in anti-tumor immunity and cancer metabolism, and lay the groundwork for further studies assessing whether these CD8+ TIL-associated microbial taxa and metabolites could serve as biomarkers or therapeutic agents for immunotherapy, increasing its efficacy in TNBC or expanding its usage in other BC subtypes. Here, CD8A is linked to neoplasm.